The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate ( Copaxone , Glatopa , and generics) about a risk of anaphylaxis. Glatiramer has…
Med Lett Drugs Ther. 2025 Feb 17; 67(1722):32 doi:10.58347/tml.2025.1722e
The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate ( Copaxone , Glatopa , and generics) about a risk of anaphylaxis. Glatiramer has been used for years to treat relapsing forms of multiple sclerosis (MS).
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations,…
Med Lett Drugs Ther. 2021 Mar 22; 63(1620):42-8
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first…
Med Lett Drugs Ther. 2017 Jun 19; 59(1523):98-101
The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as…
Med Lett Drugs Ther. 2016 Jun 6; 58(1496):71-4
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as fatigue, depression, and pain, and corticosteroids for acute exacerbations.
The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
Med Lett Drugs Ther. 2015 May 11; 57(1468):67-9
The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years…
Med Lett Drugs Ther. 2013 Jun 10; 55(1418):45-7
The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the…
Med Lett Drugs Ther. 2010 Nov 1; 52(1350):86-7
The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the same factory and packaged separately.
Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ…
Med Lett Drugs Ther. 2009 Mar 9; 51(1307):17-8
Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and…
Med Lett Drugs Ther. 2005 Feb 14; 47(1202):13-5
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Glatiramer acetate ( Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis…
Med Lett Drugs Ther. 1997 Jul 4; 39(1004):61-2
Glatiramer acetate ( Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (MS). Interferon β-1b ( Betaseron ) and interferon β-1a ( Avonex - Medical Letter, 38:63, 1996) were previously approved for this indication.
Interferon β-1a ( Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS).…
Med Lett Drugs Ther. 1996 Jul 19; 38(979):63-4
Interferon β-1a ( Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a ( Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Interferon β-1b ( Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple…
Med Lett Drugs Ther. 1993 Jul 9; 35(900):61-2
Interferon β-1b ( Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis (MS), the most common form of the disease (G Mitchell, Med Clin North Am, 77:231, 1993).